A phase-2 trial in ALS patients is sponsored by Sangamo BioSciences (NCT00748501)—Clinical Trial of SB-509 in Subjects with Amyotrophic Lateral Sclerosis (ALS). Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)-Sangamo BioSciences) designed to upregulate the expression of the gene encoding VEGF-A. The gene discussed is TF; the disease is amyotrophic lateral sclerosis.